TREATMENT OF PROGRESSIVE SYSTEMIC-SCLEROSIS BY PLASMA-EXCHANGE - LONG-TERM RESULTS IN 40 PATIENTS

被引:17
作者
GUILLEVIN, L
AMOURA, Z
MERVIEL, P
POURRAT, J
BUSSEL, A
SOBEL, A
KHUY, T
HOUSSIN, A
ALCALAY, D
STROUMZA, P
SANDERSON, F
LEVY, G
FREY, G
ANG, KS
机构
[1] CHU PURPAN,TOULOUSE,FRANCE
[2] HOP ST LOUIS,CTS,F-75475 PARIS 10,FRANCE
[3] HOP HENRI MONDOR,F-94010 CRETEIL,FRANCE
[4] HOP COCHIN,CTS,F-75674 PARIS 14,FRANCE
[5] CHU ANGERS,SERV NEPHROL,F-49036 ANGERS,FRANCE
[6] CTR REG TRANSFUS SANGUINE,POITIERS,FRANCE
[7] CLIN RESIDENCE PARC,SERV NEPHROL,MARSEILLE,FRANCE
[8] HOP CIMIEZ,SERV MED INTERNE,NICE,FRANCE
[9] CTS,ANNEMASSE,FRANCE
[10] HOP MOENSINBERG,SERV MED INTERNE,MULHOUSE,FRANCE
[11] HOP ST BRIEUC,SERV NEPHROL,ST BRIEUC,FRANCE
关键词
D O I
10.1177/039139889001300213
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
The efficacy of plasma exchanges (PE) during the course of scleroderma has only been investigated for short periods. The aim of this study was to follow patients over a long enough period to observe the course of the clinical and paraclinical symptons in the short, medium, and long term. Forty patients, 24 women and 16 men, were treated by PE and observed for 1-3, 3-12 and over 12 months. Immunological, biological and clinical course and any undesirable side effects were evaluated using a detailed questionnaire. Concomitant therapies were reported and most frequently consisted of corticosteroids, colchicine, factor XII or vasodilators (nifedipine, captopril). The therapeutic effectiveness of PE was assessed on the basis of improvements in cutaneous, digest joint, muscular, lung, cardiovascular and renal lesions. Our findings confirmed the effectiveness of shortterm PE on scleroderma (52% of the patients improved during the first 3 months). However, this improvement was transient (5% improvement between 3 and 12 months and only 2.5% over 12 months) and limited to the cutaneous and muscular lesions. Thus, PE cannot be recommended for the treatment of progressive systemic sclerosis.
引用
收藏
页码:125 / 129
页数:5
相关论文
共 19 条
[1]   USE OF CAPTOPRIL AS EARLY THERAPY FOR RENAL SCLERODERMA - A PROSPECTIVE-STUDY [J].
BECKETT, VL ;
DONADIO, JV ;
BRENNAN, LA ;
CONN, DL ;
OSMUNDSON, PJ ;
CHAO, EYS ;
HOLLEY, KE .
MAYO CLINIC PROCEEDINGS, 1985, 60 (11) :763-771
[2]  
CECERE FA, 1982, PLASMA THER TRANSFUS, V3, P401
[3]  
COFFE C, 1982, MAI JOURN ACT ECH PL
[4]   PLASMAPHERESIS AND IMMUNOSUPPRESSIVE DRUG-THERAPY IN SCLERODERMA [J].
DAU, PC ;
KAHALEH, MB ;
SAGEBIEL, RW .
ARTHRITIS AND RHEUMATISM, 1981, 24 (09) :1128-1136
[5]  
GRUNFELD JP, 1980, NOUV PRESSE MED, V9, P2658
[6]   TREATMENT OF PROGRESSIVE SYSTEMIC-SCLEROSIS WITH PLASMA-EXCHANGE - 7 CASES [J].
GUILLEVIN, L ;
LEON, A ;
LEVY, Y ;
BLETRY, O ;
GAYRAUD, M ;
ANDREU, G ;
GODEAU, P .
INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 1983, 6 (06) :315-318
[7]  
GUILLEVIN L, 1982, REV MED INTERNE, V3, P272
[8]   THE IMMUNOPATHOLOGY OF PROGRESSIVE SYSTEMIC-SCLEROSIS (PSS) [J].
HAYNES, DC ;
GERSHWIN, ME .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 1982, 11 (03) :331-351
[9]  
LOCKWOOD CM, 1981, CLIN IMMUNOL ALLERGY, V1, P433
[10]   REVERSAL OF VASCULAR AND RENAL CRISES OF SCLERODERMA BY ORAL ANGIOTENSIN-CONVERTING-ENZYME BLOCKADE [J].
LOPEZOVEJERO, JA ;
SAAL, SD ;
DANGELO, WA ;
CHEIGH, JS ;
STENZEL, KH ;
LARAGH, JH .
NEW ENGLAND JOURNAL OF MEDICINE, 1979, 300 (25) :1417-1419